|

Tofacitinib in Juvenile Idiopathic Arthritis

RECRUITINGSponsored by Consorci Sanitari de l'Alt Penedès i Garraf
Actively Recruiting
SponsorConsorci Sanitari de l'Alt Penedès i Garraf
Started2026-02-02
Est. completion2027-12
Eligibility
Healthy vol.Accepted

Summary

This study aims to evaluate, using real-world clinical practice data, the efficacy of tofacitinib in improving the clinical control of juvenile idiopathic arthritis (JIA) after 12 months of treatment.

Eligibility

Healthy volunteers accepted
Inclusion criteria:

Diagnosis of juvenile idiopathic arthritis (JIA) documented in the medical record by the treating rheumatologist.

Documentation in the medical record of the medical indication for tofacitinib treatment, with a diagnostic justification related to JIA.

Age under 18 years at the time of the treatment indication with tofacitinib.

Exclusion criteria:

Participants diagnosed with any of the following conditions:

Reactive arthritis

Arthritis associated with inflammatory bowel disease

Arthritis associated with another autoimmune disease

Conditions2

ArthritisJuvenile Idiopathic Arthritis (JIA)

Interventions1

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.